EVIDENCE FOR POSTSYNAPTIC MEDIATION OF THE HYPOTHERMIC EFFECT OF 5-HT1A RECEPTOR ACTIVATION

被引:84
作者
OCONNELL, MT [1 ]
SARNA, GS [1 ]
CURZON, G [1 ]
机构
[1] INST NEUROL, DEPT NEUROCHEM, QUEEN SQ, LONDON WC1N 3BG, ENGLAND
关键词
FEEDING; 5-HT1A AGONISTS; 5-HT1A ANTAGONISTS; 5-HT BEHAVIOR; TEMPERATURE;
D O I
10.1111/j.1476-5381.1992.tb14382.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The 5-HT1A ligand BMY 7378 (8-[2[4-(2-methoxyphenyl)-l-piperazinyl]ethyl]8-azaspirol [4,5]-decane-7,9-dione dihydrochloride, 0.032-2 mg kg-1, s.c.) caused hyperphagia, a response to the activation of presynaptic 5-HT1A receptors. 2 BMY 7378 (8 mg kg-1, s.c.) and the 5-HT1A agonist (8-hydroxy-2-(di-n-propylamino) tetralin(8-OH-DPAT), 0.10 and 0.25 mg kg-1 s.c.) also caused hypothermia. This was inhibited by (-)-pindolol (1 mg kg-1, i.p.) and not prevented by pretreatments with p-chlorophenylalanine which grossly depleted 5-hydroxytryptamine (5-HT) from terminal regions. The hypothermic effects are explicable by activation of postsynaptic 5-HT1A receptors. Infusion of BMY 7378 (8-64-mu-g) into the dorsal raphe was without convincing hypothermic effect. 3 BMY 7378 (8 mg kg-1, s.c.) inhibited another effect of activation of postsynaptic 5-HT1A receptors, i.e., the induction of components of the 5-HT syndrome by 8-OH-DPAT (0. 5, 1.0 mg kg-1, s.c.) which suggests that BMY 7378 has antagonistic as well as agonistic effects at these sites. 4 Partial agonist properties of BMY 7378 at postsynaptic sites were also indicated by doses for hypothermia being much greater than those for hyperphagia i.e., ED50 (hypothermia) > 2 mg kg-1, ED50 (hyperphagia) = 0.010 mg kg-1. This contrasts with the similar ED50 values for both the hypothermic (ED50=0.08-0.10 mg kg-1) and hyperphagic (ED50=0.06-0.10 mg kg-1) effects of 8-OH-DPAT. 5 The evidence obtained for mediation of the hypothermic response to 5-HT1A agonists by postsynaptic sites is relevant to the interpretation of the effects on it of antidepressant treatments and depressive illness.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 49 条
[41]   FURTHER INVESTIGATION OF THE INVIVO PHARMACOLOGICAL PROPERTIES OF THE PUTATIVE 5-HT1A ANTAGONIST, BMY 7378 [J].
SHARP, T ;
BACKUS, LI ;
HJORTH, S ;
BRAMWELL, SR ;
GRAHAMESMITH, DG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 176 (03) :331-340
[42]   DIFFERENTIAL-EFFECTS OF PARA-CHLOROPHENYLALANINE ON INDOLEAMINES IN BRAIN-STEM NUCLEI AND SPINAL-CORD OF RATS .1. BIOCHEMICAL AND BEHAVIORAL-ANALYSIS [J].
STEINMAN, JL ;
CARLTON, SM ;
HABER, B ;
WILLIS, WD .
BRAIN RESEARCH, 1987, 426 (02) :297-309
[43]   QUANTITATIVE MORPHOMETRIC ANALYSIS OF 2 TYPES OF SEROTONIN-IMMUNOREACTIVE NERVE-FIBERS DIFFERENTIALLY RESPONDING TO PARA-CHLOROPHENYLALANINE TREATMENT IN THE RAT-BRAIN [J].
TOHYAMA, I ;
KAMEYAMA, M ;
KIMURA, H .
NEUROSCIENCE, 1988, 26 (03) :971-991
[44]   THE INVOLVEMENT OF SUBTYPES OF THE 5-HT1 RECEPTOR AND OF CATECHOLAMINERGIC SYSTEMS IN THE BEHAVIORAL-RESPONSE TO 8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN IN THE RAT [J].
TRICKLEBANK, MD ;
FORLER, C ;
FOZARD, JR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 106 (02) :271-282
[45]  
VANDERMAELEN CP, 1987, NEUR ABSTR, V13
[46]   PRESYNAPTIC 5-HT AUTORECEPTORS ON SEROTONERGIC CELL-BODIES AND OR DENDRITES BUT NOT TERMINALS ARE OF THE 5-HT1A SUBTYPE [J].
VERGE, D ;
DAVAL, G ;
PATEY, A ;
GOZLAN, H ;
ELMESTIKAWY, S ;
HAMON, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 113 (03) :463-464
[47]   EVIDENCE FOR THE LOCALIZATION OF 5HT1A BINDING-SITES ON SEROTONIN CONTAINING NEURONS IN THE RAPHE DORSALIS AND RAPHE CENTRALIS NUCLEI OF THE RAT-BRAIN [J].
WEISSMANNNANOPOULOS, D ;
MACH, E ;
MAGRE, J ;
DEMASSEY, Y ;
PUJOL, JF .
NEUROCHEMISTRY INTERNATIONAL, 1985, 7 (06) :1061-1072
[48]   THE EFFECT OF 8-OH-DPAT ON TEMPERATURE IN THE RAT AND ITS MODIFICATION BY CHRONIC ANTIDEPRESSANT TREATMENTS [J].
WOZNIAK, KM ;
AULAKH, CS ;
HILL, JL ;
MURPHY, DL .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1988, 30 (02) :451-456
[49]   BMY-7378, A BUSPIRONE ANALOG WITH HIGH-AFFINITY, SELECTIVITY AND LOW INTRINSIC ACTIVITY AT THE 5-HT1A RECEPTOR IN RAT AND GUINEA-PIG HIPPOCAMPAL MEMBRANES [J].
YOCCA, FD ;
HYSLOP, DK ;
SMITH, DW ;
MAAYANI, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 137 (2-3) :293-294